Updated 12-12-24 to reflect the chance in name from Epic Bio to Epicrispr Biotechnologies. Read the full news release here. SOUTH SAN FRANCISCO, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) —Â Epicrispr… Read More »
Orphan drug designation for Epic Bio’s FSHD candidate
Avidity Announces New Positive AOC 1001 Data
Avidity Biosciences, Inc. (Nasdaq: RNA), has announced new positive AOC 1001 data demonstrating improvement in multiple functional endpoints and favorable long-term safety and tolerability in people living with myotonic dystrophy… Read More »
The FSHD Society Celebrates Fulcrum’s Milestone in the Fight Against FSHD
Fulcrum Therapeutics has announced successful completion of patient enrollment in REACH Phase 3 trial The FSHD Society is thrilled to announce a significant milestone in the battle against FSHD. Fulcrum… Read More »
FSHD Lab Day was empowering for all
Uniting the FSHD Community in Advancing Research by Nizar Saad, PhD, Columbus, Ohio On July 8th, our lab at Nationwide Children’s Hospital (NCH) in Columbus, Ohio, in collaboration with NCH,… Read More »
Making strides toward stem cell therapies
University of Minnesota lab reports promising results in mouse FSHD studies by Fred Thys, Weymouth, Massachusetts Work by a team led by Dr. Rita Perlingeiro at the University of Minnesota… Read More »